Dr. Reddy's Lab

Walk in interview in Quality Control, Production at Dr. Reddy's Laboratories

Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.

Dr. Reddy's completed fondaparinux intellectual property purchase

  • Posted on: 19 November 2015
  • By: Shalini.Sharma

Dr. Reddy's Laboratories announced that it has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug, from its Australian partner, Alchemia Limited. Earlier, the company had signed a term sheet for this transaction in September, 2015.

Walk in interview for QA and QC for Formulations plant in Dr. Reddy’s Lab

At Dr. Reddy’s we strive every day to do what matters most to patients: accelerating access to affordable medicines and finding solutions for unmet needs.
Our Generics products bring expensive medicines within reach of patients by helping reduce the cost of therapy. Our portfolio consists of all dose forms in multiple therapeutic areas as well as biologic drugs.
We also serve patients through our partners. For one, we supply other generics companies with active pharmaceutical ingredients, which helps them quickly bring medicines to market and create affordable options to high cost medicines. We also help innovator companies get their proprietary medicines to patients faster by providing a range of products and services.

Post: QA and QC for Formulations plant based at Visakhapatnam and Hyderabad

Dr. Reddy’s Statement regarding the receipt of Temporary Restraining Order (TRO) for esomeprazole capsules

  • Posted on: 16 November 2015
  • By: Shalini.Sharma

Dr. Reddy’s Laboratories in a statement issued said that it has been made aware of an order passed by the District Court of Delaware, USA, granting a Temporary Restraining Order (TRO) with immediate effect on sales, delivery, transfer, or other disposition of its generic esomeprazole product in the US market.

NIPERs and Pharma Industries bridged to fulfill academic and industry gap

  • Posted on: 6 November 2015
  • By: admin

National Institutes for Pharmaceutical Education and Research (NIPERs) and Pharma Industries signed 17 MoU to bridge gap betwwen academic education and industrial needs. One of the critical factors in building innovation ecosystem and for Drug Discovery is Academia-Industry linkage. Department of Pharmaceuticals (DoP) for the last one year has actively engaged both the NIPERs and the Pharma Industry to build partnership in areas of education, research and development.

Vacancy as Scientific Business Officer-Ahmendabad Derma in Dr. Reddy’s Lab

At Dr. Reddy’s we strive every day to do what matters most to patients: accelerating access to affordable medicines and finding solutions for unmet needs.
Our Generics products bring expensive medicines within reach of patients by helping reduce the cost of therapy. Our portfolio consists of all dose forms in multiple therapeutic areas as well as biologic drugs.
We also serve patients through our partners. For one, we supply other generics companies with active pharmaceutical ingredients, which helps them quickly bring medicines to market and create affordable options to high cost medicines. We also help innovator companies get their proprietary medicines to patients faster by providing a range of products and services.

Post: Scientific Business Officer-Ahmendabad Derma A (13165)

Pages